BCL11B and acute lymphoblastic leukemia: In particular, in the standard risk group of thymic T-ALL, BCL11b was of relevant prognostic impact: 62% of BCL11b-high patients were alive after 5 years, whereas survival was only 20% at 5 years in the BCL11b-low subgroup.